<?xml version="1.0" encoding="UTF-8"?>
<p>Despite a lack of evidence demonstrating any increased susceptibility to COVID‐19,
 <xref rid="apt15779-bib-0050" ref-type="ref">
  <sup>50</sup>
 </xref> medications used in the management of IBD have been shown to increase the risk of respiratory tract infections and serious infections to varying degrees (Table 
 <xref rid="apt15779-tbl-0002" ref-type="table">2</xref>). However, theoretically, there may also be some beneficial effects seen with certain immunosuppressive medications, given the cause of death in COVID‐19 is a cytokine storm resulting in ARDS.
</p>
